SEP 18, 2015 09:15 PM PDT

Test Could Gauge Breast Cancer Relapse

Women successfully treated for breast cancer know that it could return. New research published in the journal Clinical Epigenetics and reported in Drug Discovery News may lead to a simple blood test to determine the risk of such recurrence. The test could also predict the cancer invading other organs such as the lungs, bone or brain. It could have enormous implications for improving the future treatment of women with all kinds of breast cancer, a disease that affects one in eight women.
This micrograph shows a lymph node invaded by ductal breast carcinoma, with an extension of the tumor beyond the lymph node. 
The study was conducted at the Translational Genomics Research Institute (TGen). Researchers identified 21 DNA hypermethylation hotspots --  which are gene locations along the 3 billion chemical bases of DNA -- with increased levels of methylation that could indicate metastatic breast cancer.
 
According to Dr. Bodour Salhia, an assistant professor in TGen's Integrated Cancer Genomics Division, and the study's senior author, "These findings could lead to a highly sensitive blood-based test panel -- a type of liquid biopsy -- which could help improve the care of women with breast cancer. This 21-gene signature is a potential biomarker that could indicate patients who are at high risk of cancer recurrence, either in the breast or elsewhere in the body, and who might benefit from additional therapy to eliminate the potential of recurrence. This would be critically important information for oncologists as they consider ongoing treatments post surgery and/or the completion of each round of chemotherapy."
 
Biomarkers are indicator molecules, including proteins or DNA, that can be measured in blood, body fluids or tissue samples and can be used to diagnose or measure a particular disease or the effects of a treatment. Using whole-genome sequencing, researchers sought biomarkers in the cell-free strands of DNA (cfDNA) circulating in pooled samples of blood from 40 metastatic breast cancer patients. They then compared them to samples from 40 healthy individuals and 40 disease-free breast cancer survivors.
 
Despite the huge quantity of information obtained from other gene signatures now available, none can exactly predict the clinical course of an individual, the researchers said. Thus, clinicians rely on the presence of tissue at a single time point. Some patients considered high-risk do very well with standard therapy and never experience a recurrence, while some patients with low-risk profiles succumb to the disease. The TGen study identified 21 genes that were "differentially methylated," those that could have altered levels of methylation, all of which were consistently higher in patients with metastatic breast cancer as compared to the levels in healthy individuals and cancer-free survivors.
Dr. Sahlia concluded, "This study is one of the first whole-genome descriptions of methylation in blood, and the first unbiased study reporting on the circulating methylome of metastatic breast cancer. There is likely a predictive clinical window of opportunity to detect microscopic disease before the cancer spreads throughout the body. The next step would be to further validate the results using individual samples.”
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 24, 2018
Cancer
JUL 24, 2018
FDA Approves New Drug for Refractory/Relapsed AML
A new drug and new drug class have been approved by the FDA for relapsed or refractory AML patients with an IDH1 mutation. The new drug offers options for patients....
JUL 26, 2018
Genetics & Genomics
JUL 26, 2018
When a Cancer Gene Switches Sides
All cells carry a gene named p53, which has a vital role in shielding the body from cancer. But it can betray cells too....
AUG 08, 2018
Immunology
AUG 08, 2018
Doxorubicin Causes Heart Toxicity by Immune System Disruption
Chemotherapy drug Doxorubicin disrupts metabolism that controls immune responses in the heart leading to heart toxicity....
OCT 03, 2018
Cell & Molecular Biology
OCT 03, 2018
Single Cell Modified in CAR T Therapy Causes Deadly Relapse
One cell meant a very different outcome for a patient that was the recipient of a cutting-edge cancer therapy....
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
DEC 06, 2018
Microbiology
DEC 06, 2018
A Bacterial Protein can Encourage Cancer Development
It's been suggested that a fifth of all cancers are caused by microbial infections, and new work indicates that the estimate is probably low....
Loading Comments...